Clinical Outcomes of Preservation Versus Resection of Portal/Superior Mesenteric Vein During Pancreaticoduodenectomy in Pancreatic Cancer Patients Who Respond to Neoadjuvant Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06372886

Enrollment

264

Registered

2024-04-18

Start date

2012-01-01

Completion date

2024-03-01

Last updated

2024-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Head Cancer Patients Who Underwent Surgery After Neoadjuvant Treatment

Brief summary

1. There is a lack of evidence on the need to perform portal/superior mesenteric vein (PV/SMV) resection routinely in pancreatic ductal adenocarcinoma (PDAC) patients with venous involvement who responded to neoadjuvant treatment (NAT). 2. There is no significant differences in R0 rate, 5-year overall survival and recurrence-free survival between the PV/SMV preservation (PVP) group and PV/SMV resection (PVR) group. 3. PVP group showed significantly better 5-year PV/SMV stenosis free survival than the PVR group. 4. We propose that if dissection is possible and there is a high likelihood of achieving R0 resection after NAT, routine PVR may be unnecessary in PDAC patients with venous involvement.

Interventions

PROCEDUREportal/superior vein resection

portal/superior vein resection

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 79 Years

Healthy volunteers

Inclusion criteria

* Pancreatic head cancer patients who underwent surgery after neoadjuvant treatment between January 2012 and December 2022 at Seoul National University Hospital

Exclusion criteria

* Metastatic unresectable and locally advanced pancreatic cancer * Resectable pancreatic cancer without portal/superior mesenteric vein invasion * Cancer aggravation after neoadjuvant treatment * Portal/superior mesenteric vein encasing and narrowing after neoadjuvant treatment * Patients who underwent palliative surgery * Non-pancreatic ductal adenocarcinoma patients * Patients who death within 30 days of surgery * Loss of follow-up patients * Patients who underwent resection for suspected main artery and adjacent organ invasion

Design outcomes

Primary

Measure	Time frame	Description
5-year overall survival	assessed up to 60months	from diagnosis to any cause of death
5-year portal/superior mesenteric vein stenosis free survival	assessed up to 60months	from surgery to stenosis

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026